Patients who are not on oxygen support or are in home settings should not be recommended Remdesivir, the latest clinical guidance for the management of adult Covid-19 patients says.
Classifying active Covid-19 patients into three broad groups of mild, moderate and severe, the Union health ministry has issued fresh clinical guidance for the management of adult Covid-19 patients, underlying which patients need which medication and what should not be done in a specific situation.
Ivermectin or HCQ
Clarifying that this is based on low certainty of evidence, the guideline said that Tab Ivermectin (200 mcg/kg once a day for 3 days) may be given to patients who have mild symptoms and are being treated at home.
An alternative to Ivermectin is Tab HCQ (400 mg BD 1 day f/b 400 mg OD for 4 days) unless contraindicated.
For these mild patients, inhalational Budesonide (given via Metered dose inhaler/ Dry powder inhaler) at a dose of 800 mcg BD for 5 days) may be given if symptoms (fever and/or cough) are persistent beyond 5 days of disease onset.
📢 Latest Clinical Guidance for Management of Adult #COVID19 Patients‼️
For more details: https://t.co/GXFhozHWVN#Unite2FightCorona #StaySafe pic.twitter.com/N64dUuATti
— #IndiaFightsCorona (@COVIDNewsByMIB) April 22, 2021
